These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12873864)

  • 1. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
    Frisoni GB; Padovani A; Wahlund LO
    Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biomarkers in cerebrospinal fluid and blood in memory complaints].
    Zetterberg H; Andreasen N; Blennow K
    Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836
    [No Abstract]   [Full Text] [Related]  

  • 3. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
    Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
    Herukka SK; Hallikainen M; Soininen H; Pirttilä T
    Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study.
    Buerger K; Ewers M; Andreasen N; Zinkowski R; Ishiguro K; Vanmechelen E; Teipel SJ; Graz C; Blennow K; Hampel H
    Neurology; 2005 Nov; 65(9):1502-3. PubMed ID: 16275849
    [No Abstract]   [Full Text] [Related]  

  • 8. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
    Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
    J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.
    Moonis M; Swearer JM; Dayaw MP; St George-Hyslop P; Rogaeva E; Kawarai T; Pollen DA
    Neurology; 2005 Jul; 65(2):323-5. PubMed ID: 16043812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
    Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
    Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?
    Spies PE; Verbeek MM; Olde Rikkert MG; Claassen JA
    J Am Geriatr Soc; 2010 Aug; 58(8):1619-20. PubMed ID: 20942893
    [No Abstract]   [Full Text] [Related]  

  • 12. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
    Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
    Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers for mild cognitive impairment.
    Blennow K
    J Intern Med; 2004 Sep; 256(3):224-34. PubMed ID: 15324365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
    MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of plasma Abeta40 and Abeta42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Kester MI; Verwey NA; van Elk EJ; Scheltens P; Blankenstein MA
    Neurobiol Aging; 2010 Apr; 31(4):539-40; author reply 541. PubMed ID: 18963255
    [No Abstract]   [Full Text] [Related]  

  • 17. New tests for AD.
    Health News; 2006 Apr; 12(4):15. PubMed ID: 16578901
    [No Abstract]   [Full Text] [Related]  

  • 18. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
    Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
    Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New tests for Alzheimer's disease.
    Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?
    Borroni B; Di Luca M; Padovani A
    Eur J Pharmacol; 2006 Sep; 545(1):73-80. PubMed ID: 16831417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.